- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Peroxisome proliferator-activated receptor α agonist-induced histidine decarboxylase gene expression in the rat and mouse liver. (Pubmed Central) - Oct 1, 2020
By analysis of the data from the Toxicogenomics Database (TG-GATEs), histidine decarboxylase gene (Hdc) was identified as largely and commonly upregulated by three fibrates, clofibrate, fenofibrate, and WY-14,643, which are known to induce hepatocellular hypertrophy and proliferation via stimulation of peroxisome proliferator-activated receptor α (PPARα) in rodents...Surprisingly, the fibrates caused hepatic hypertrophy but no induction of Hdc mRNA at all in mice. These results revealed that the changes in the histidine catabolism by PPARα agonists might be partially, but not directly, involved in the hepatocyte proliferation in rats, and there is a large genetic distance even between rat and mouse.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Predicting the environmental emissions arising from conventional and nanotechnology-related pharmaceutical drug products. (Pubmed Central) - Sep 30, 2020
Compared to the conventional product Lipidil® 200, the pharmaceutical product Lipidil 145 One® and Ecocaps take advantage of nanotechnology to improve uptake and bioavailability of the drug in humans...The fish embryo toxicity test revealed a lower aquatic toxicity for the metabolite fenofibric acid and therefore an improved toxicity profile...In a streamlined life cycle assessment, the lowered dose in combination with a lowered drug-to-metabolite ratio observed for Ecocaps led to a reduction of the full life cycle impacts of fenofibrate with a reduction of 18% reduction in the global warming potential, 61% in ecotoxicity, and 15% in human toxicity. The integrated environmental assessment framework highlights the outstanding potential of advanced modeling technologies to determine environmental impacts of pharmaceuticals during early drug development using preclinical in vitro data.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Clinical, Journal: CD44 cells determine fenofibrate-induced microevolution of drug-resistance in prostate cancer cell populations. (Pubmed Central) - Sep 30, 2020
However, they also revealed the resistance of CD44 prostate cancer stem cells to the combined docetaxel/fenofibrate treatment, accompanied by docetaxel/fenofibrate-induced microevolution of hyper-resistant CD44 progenies. Thus, the balance between the sensitivity of CD44 prostate cancer cells to chemotherapeutics and the adaptation of CD44 stem-like cells to metabolic stress determines the response of prostate tumors to metabolic chemotherapy.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Circulatory markers of diabetic retinopathy caused by Type 2 Diabetes Mellitus (Abstract Channel) - Sep 28, 2020 - Abstract #EURETINA2020EURETINA_847;
Identifying circulatory biomarkers of PDR contributes to greater understanding of mediators of DR and could lead to the development of additional therapeutics.Our study has shown that several biochemical markers especially those looking at dyslipidemia, renal function, ESR and liver function are worth monitoring in T2DM patients and could point towards a diagnosis of retinopathy. Further prospective studies looking at changes in these biochemical markers and the development and progression of retinopathy would be needed to understand the history of disease and further elucidate the use of circulatory biomarkers as predictive markers for sight-threatening disease.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Design, synthesis and evaluation of 5-(4-hydroxyphenyl)-3H-1,2-dithiole-3-thione-Based fibrates as potential hypolipidemic and hepatoprotective agents. (Pubmed Central) - Sep 26, 2020
All the synthesized compounds were preliminarily screened by using the Triton WR-1339-induecd hyperlipidemia model, in which T1 exhibited more potent hypolipidemic property than positive drug fenofibrate (FF)...In the livers of T1-administrated rat, the levels of PPARα related to lipids metabolism were up-regulated. Additional effects such as antioxidant, anti-inflammatory and HS releasing action confirmed and reinforced the activity of T1 as a potential multifunctional hypolipidemic and hepatoprotective agent.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Large triglyceride-rich lipoproteins in hypertriglyceridemia are associated with the severity of acute pancreatitis in experimental mice. (Pubmed Central) - Sep 25, 2020
Gpihbp1-/- mice with triglyceride levels below 2000 mg/dL had milder pancreatic injury and less incidence of pancreatic necrosis than those with triglyceride levels above 2000 mg/dL, similar to Gpihbp1-/-mice with triglyceride levels above 2000 mg/dL but with fenofibrate administration. These findings demonstrated that hypertriglyceridemia subtypes with large TRL particles could affect acute pancreatitis progression and that chylomicrons showed more cytotoxicity than VLDL by releasing more FFAs.
- |||||||||| budesonide / Generic mfg., Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi
Clinical, Journal: Risk of sepsis among patients with COPD treated with fixed combinations of inhaled corticosteroids and long-acting Beta2 agonists. (Pubmed Central) - Sep 23, 2020
Patients receiving fluticasone/salmeterol had a significant higher risk of sepsis related respiratory organ dysfunction, lower respiratory tract infection, genitourinary tract infection, bacteremia and skin infection. In conclusion, long-term treatment with budesonide/formoterol was associated with lower rates of sepsis and deaths than fluticasone/salmeterol in patients with COPD.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Review, Journal: Conjugation to Branched Glycerol Oligomers, a Novel Strategy for Extremely Hydrophobic Agents (Pubmed Central) - Sep 23, 2020
Water-solubility of fenofibrate, one of the most hydrophobic medicines in clinical use, was facilitated by a factor of more than 2000, and its lipid-lowering effect in vivo improved more than ten-fold, by simply conjugating with branched glycerol trimer, for instance. Here we will briefly introduce the basic concepts and our successful experiences of applying branched glycerol oligomers including antitumor agents in terms of water-solubility, pharmacological effects, and pharmacokinetics, and merits and current issues will be discussed in this review.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Fenofibrate impairs liver function and structure more pronounced in old than young rats. (Pubmed Central) - Sep 16, 2020
Although 0.5 % FN decreased serum Chol concentration, it increased serum ALP activity and impaired liver structure in both in both age groups of rats. Thus, FN treatment should be under the control of liver function, especially in older patients.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Very Severe Hypertriglyceride-Induced Pancreatitis With Quick Resolution on Insulin Therapy Alone () - Sep 15, 2020 - Abstract #ACG2020ACG_820;
Patient was intubated and started on Meropenem for concern over aspiration pneumonia versus necrotizing pancreatitis...Patient was successfully treated for both pancreatitis and pneumonia, and discharged on hospital day 14 on omeprazole and fenofibrate...However, in those cases, it took 6 days of insulin therapy until goal levels were achieved. In this presented case, goal levels were achieved by day 3.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
[VIRTUAL] Lipoprotein Lipase Deficiency as a Rare Cause of Acute Pancreatitis () - Sep 15, 2020 - Abstract #ACG2020ACG_751;
Despite the use of high intensity statin, fenofibrate, diet restriction and insulin pump, triglyceride levels has been very difficult to control...There have been some studies that suggested high dose antioxidant therapy could potentially help lower the level of triglycerides and prevent recurrent episodes of acute pancreatitis in that particular group of patients. It is also critical to make the diagnosis as soon as possible for early medical interventions during childhood and genetic counseling and testing for family members.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Examination of clinical effects of ICS / LABA / LAMA preparations () - Sep 11, 2020 - Abstract #WAC2020WAC_1172;
Analysis of genome-wide datasets led to the elucidation of the underlying mechanisms and identified six potential targeted drugs for the treatment of early PDAC. The password to see abstracts was announced to registrants by email.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, Praluent (alirocumab) / Sanofi, Regeneron
Clinical, Journal: Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol. (Pubmed Central) - Sep 1, 2020
P4
Trial registration Clinicaltrials.gov, NCT02642159. Registered December 24, 2015, https://clinicaltrials.gov/ct2/show/NCT02642159.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi, tacrolimus / Generic mfg., everolimus / Generic mfg.
[VIRTUAL] Outcomes of everolimus after heart transplantation (E-Poster Hall) - Aug 29, 2020 - Abstract #TTS2020TTS_1493;
Frequent indications for EVL were CKD and CAV. Concentration-controlled EVL (C0 target 3.0-6.5 ng/ml) in combination with reduced TAC achieved good efficacy and safety, higher C0 target was associated with frequent infectious complications.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Fibrane the reduced derivative of fenofibrate. (Pubmed Central) - Aug 28, 2020
Concentration-controlled EVL (C0 target 3.0-6.5 ng/ml) in combination with reduced TAC achieved good efficacy and safety, higher C0 target was associated with frequent infectious complications. No abstract available
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Attenuated Lymphatic Proliferation Ameliorates Diabetic Nephropathy and High-Fat Diet-Induced Renal Lipotoxicity. (Pubmed Central) - Aug 27, 2020
We used PPARα agonist, fenofibrate, to unravel the linkage between lipotoxicity and lymphangiogenesis...Enhanced expression of M1 phenotype in RAW264.7 cells correlated with increased lymphatic growth. A causal relationship between lipotoxicity and lymphatic proliferation with a cellular link to macrophage activation can be speculated; pro-inflammatory M1 type macrophage is involved in the development of lymphangiogenesis through stimulation of VEGF-C and by its transdifferentiation into lymphatic endothelial cells.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
Journal: Trends over time in COPD treatment choices by respiratory physicians: An analysis from the COLIBRI-COPD French cohort. (Pubmed Central) - Aug 27, 2020
A causal relationship between lipotoxicity and lymphatic proliferation with a cellular link to macrophage activation can be speculated; pro-inflammatory M1 type macrophage is involved in the development of lymphangiogenesis through stimulation of VEGF-C and by its transdifferentiation into lymphatic endothelial cells. Changes over time in therapeutic profiles suggest that new evidence from scientific publications and recommendations may have had a rapid impact on clinical practice.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
[VIRTUAL] Beclomethasone, formoterol and glycopyrronium: ceiling effect in small airways of COPD patients (Channel 2) - Aug 21, 2020 - Abstract #ERS2020ERS_5541;
On top salbutamol did not significantly (P>0.05) improve R5-19Hz neither at peak (-12.9±2.6% vs. pre-salbutamol) nor at trough (-31.6±6.0% vs. pre-salbutamol). Conclusion This study demonstrates that BDP/FF/GB 87/5/9 ug is capable of inducing ceiling bronchodilation at the level of small airways of severe asthmatic patients.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: A relative permittivity approach for fast drug solubility screening of solvents and excipients in lipid-based delivery. (Pubmed Central) - Aug 20, 2020
Diverse solvents and lipid-based excipients were then experimentally tested for ε and solubility using fenofibrate as model...The novel permittivity approach has demonstrated its usefulness, it has much potential in early development for ranking of suitable excipients, and it gives an initial orientation to design formulations. Future research may clarify further opportunities and limits of the novel approach for LBFs.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Sorry fenofibrate (Twitter) - Aug 20, 2020
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: SPPARM alpha: the Lazarus effect. (Pubmed Central) - Aug 20, 2020
SPPARMα offers a new paradigm for reducing residual cardiovascular risk in T2DM. PROMINENT will be critical to differentiating the first SPPARMα, pemafibrate, as a novel therapeutic class distinct from current fibrates.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis, Trelegy Ellipta (fluticasone furoate/umeclidinium bromide/vilanterol) / GSK, Innoviva
Clinical, Clinical guideline, Journal: Pharmacologic Management of COPD: An Official American Thoracic Society Clinical Practice Guideline. (Pubmed Central) - Aug 15, 2020
The task force made recommendations on the pharmacologic treatment of COPD based on currently available evidence. Additional research in populations that are under-represented in clinical trials is needed, including studies in COPD patients 80 years of age and older, those with multiple chronic health conditions, and those with a co-diagnosis of COPD and asthma.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Metabolomic-based assessment reveals dysregulation of lipid profiles in human liver cells exposed to environmental obesogens. (Pubmed Central) - Aug 15, 2020
Contrarily, perfluorooctane sulfonic acid and the pharmaceutical fenofibrate appeared to lower total lipid concentrations, especially those belonging to the acylcarnitine, ceramide, triglyceride, and phosphatidylcholine groups...This integrated omics analysis provides unique mechanistic insight into the potential of these environmental pollutants to promote diseases like obesity and NAFLD. Furthermore, this study provides a significant contribution to advance the understanding of molecular signatures related to obesogenic chemicals and to the development of alternatives to in vivo experimentation.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Impaired peroxisomal fitness in obese mice, a vicious cycle exacerbating adipocyte dysfunction via oxidative stress. (Pubmed Central) - Aug 12, 2020
In response to fenofibrate (a peroxisomal proliferator) treatment, WAT of HFD-fed wild-type mice showed not only increases in peroxisomal biogenesis and FAO but also attenuated features of adipocyte dysfunction and obesity...However, these results were not observed in PPAR-α null obese mice. Innovation and Adipose tissue peroxisomal homeostasis plays an important role in attenuating the features of obesity, and it can be a potential therapeutic target of obesity.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Preclinical, Journal: Anti-inflammatory Mechanism of Ruzu Bitters on Diet-Induced Nonalcoholic Fatty Liver Disease in Male Wistar Rats. (Pubmed Central) - Aug 11, 2020
RHB significantly (p < 0.05) reduced body weight and liver index, inhibited oxidative stress, boosted antioxidant enzymes by increasing the activity and level of SOD and GSH, reduced proinflammatory markers (IL-2, IL-6, TNF-α), and reversed histological alterations induced by NAFLD in rat liver. In conclusion, the anti-inflammatory activity of RHB in the prevention of NAFLD in rats has been confirmed.
- |||||||||| micronized fenofibrate / Generic mfg., fenofibrate / Generic mfg.
Biomarker, Trial completion date, Trial primary completion date: Fenofibrate in Type 2 Diabetes (clinicaltrials.gov) - Aug 8, 2020
P4, N=40, Recruiting,
Our research suggests that fenofibrate could serve as an effective adjunct therapy for ocular oxidative stress-related disorders, such as DR. Trial completion date: Sep 2020 --> Mar 2021 | Trial primary completion date: Jun 2020 --> Dec 2020
- |||||||||| simvastatin / Generic mfg., Triglide (fenofibrate) / Vectura, Shionogi
Journal: A PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD Lipid. (Pubmed Central) - Aug 4, 2020
We identified a common variant at the PPARA locus (rs6008845, C/T) displaying a study-wide significant influence on the effect of fenofibrate on major cardiovascular events (MACE) among 3,065 self-reported white subjects treated with simvastatin and randomized to fenofibrate or placebo in the ACCORD-Lipid trial...The Genotype-Tissue Expression (GTEx) dataset revealed regulatory functions of rs6008845 on PPARA expression in many tissues. In summary, we have found a common PPARA regulatory variant that influences the cardiovascular effects of fenofibrate and that could be used to identify T2D patients who would derive benefit from fenofibrate treatment, in addition to those with atherogenic dyslipidemia.
- |||||||||| Enerzair Breezhaler (glycopyrrolate/indacaterol/mometasone) / Novartis
[VIRTUAL] Diagnosis and drug therapy based on the pathology of ACO (p.608) - Aug 2, 2020 - Abstract #WAC2020WAC_220;
ACO may be useful in combination with LAMA in patients who are poorly controlled with medium-dose ICS / LABA In that sense, the triple preparation of ICS / LABA / LAMA can be said to be a useful therapeutic agent for ACO. In this lecture, In addition to diagnosis and treatment based on the condition, we report on the current problems and future prospects.
- |||||||||| doxycycline / Generic mfg., Pierre Fabre
Journal: Effect of doxycyline in chronic obstructive pulmonary disease - An exploratory study. (Pubmed Central) - Aug 2, 2020
These data suggest that the improvement in lung function and quality of life in COPD patients may probably be attributed to the antioxidant, anti-inflammatory and anti-MMP activity of doxycycline. The potential therapeutic role of long-term doxycycline, in addition to its traditional antibiotic effect, definitely warrants further attention.
- |||||||||| Triglide (fenofibrate) / Vectura, Shionogi
Journal: Partial impairment of insulin receptor expression mimics fasting to prevent diet-induced fatty liver disease. (Pubmed Central) - Jul 30, 2020
Consistently, and unlike in control mice, the PPARα activator fenofibrate fails to further affect hepatic lipid accumulation in PerIRKO mice. Taken together, and opposing previously established diabetogenic features of insulin resistance, incomplete impairment of insulin signaling may mimic central aspects of calorie restriction to limit hepatic lipid accumulation during conditions of metabolic stress.
|
